These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27388147)

  • 21. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
    Civan J; Hann HW
    Expert Opin Drug Saf; 2015 Jun; 14(6):865-75. PubMed ID: 25826452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.
    Salpini R; Battisti A; Colagrossi L; Di Carlo D; Fabeni L; Piermatteo L; Cerva C; Lichtner M; Mastroianni C; Marignani M; Maylin S; Delaugerre C; Morisco F; Coppola N; Marrone A; Angelico M; Sarmati L; Andreoni M; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Viral Hepat; 2019 Jul; 26(7):846-855. PubMed ID: 30974483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
    Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
    Mozessohn L; Chan KK; Feld JJ; Hicks LK
    J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
    Masarone M; De Renzo A; La Mura V; Sasso FC; Romano M; Signoriello G; Rosato V; Perna F; Pane F; Persico M
    BMC Gastroenterol; 2014 Feb; 14():31. PubMed ID: 24533834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
    Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
    World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
    Liu CY; Chandrasekar PH; Masood A; Schiffer CA
    J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
    Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
    World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.
    Sarrecchia C; Cappelli A; Aiello P
    J Infect Chemother; 2005 Aug; 11(4):189-91. PubMed ID: 16133710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
    Guarino M; Picardi M; Vitello A; Pugliese N; Rea M; Cossiga V; Pane F; Caporaso N; Morisco F
    Ann Hepatol; 2017; 16(2):198-206. PubMed ID: 28233742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E; Cetinkaya RA
    Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of rituximab-induced hepatitis B flare after antiviral discontinuation in rheumatic patients with chronic hepatitis B virus.
    Lan TY; Chang TW; Tseng TC; Lee TJ; Kao JH; Cheng CF; Huang SC; Shen CY; Lu CH; Yang HC; Li KJ; Hsieh SC
    Clin Exp Rheumatol; 2024 Sep; 42(9):1830-1837. PubMed ID: 38855955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.